• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Is Powder Use Associated with Ovarian Cancer?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Evidence for a relationship between use of powder (usually talc and/or cornstarch) in the genital area and ovarian cancer has not been confirmed in cohort studies
  • O’Brien et al. (JAMA, 2020) investigated the association between use of powder in the genital area and ovarian cancer using prospective observational data

METHODS:

  • Data pooled from 4 large, US-based cohort studies
    • Nurses’ Health Study
      • Enrollment 1976 | Follow-up 1982 to 2016 | n = 81,869
    • Nurses’ Health Study II
      • Enrollment 1989 | Follow-up 2013 to 2017 | n = 61,261
    • Sister Study
      • Enrollment 2003 to 2009 | Follow-up 2003 to 2017 | n = 40,647
    • Women’s Health Initiative Observational Study
      • Enrollment 1993 to 1998 | Follow-up 1993 to 2017 | n = 73,267
  • Exposures
    • Ever use of powder in the genital area
    • Long-term: ≥20 years use
    • Frequent: ≥1/week use
  • Study design and data analysis
    • Covariate-adjusted hazard ratio (HRs) and 95% CIs were estimated using Cox proportional hazards models
    • To harmonize the 4 studies and account for different designs, estimated HRs were used | Calculations were based on an estimated risk that a woman will develop ovarian cancer by age 70 in both the exposed and unexposed groups
  • Primary outcome
    • Incident ovarian cancer

RESULTS:

  • Total of 252,745 women | Median age at baseline: 57 years
    • 38% self-reported use of powder in the genital area
    • Long-term use: 10%
    • Frequent use: 22%
  • During a median of 11.2 years of follow-up (3.8 million person-years at risk), 2168 women developed ovarian cancer (58 cases/100,000 person-years)
  • Ovarian cancer incidence
    • Ever users: 61 cases/100,000 person-years 
    • Never users: 55 cases/100,000 person-years
    • Estimated risk difference at age 70 years: 0.09% (95% CI, −0.02% to 0.19%)
    • Estimated HR 1.08 (95% CI, 0.99 to 1.17)
    • Restricted to medically confirmed ovarian cancer cases, HR was lower | HR, 1.05 (95% CI, 0.96 to 1.16)
  • The estimated HR vs to never use  
    • Frequent use 1.09 (95% CI, 0.97 to 1.23)
    • Long-term use 1.01 (95% CI, 0.82 to 1.25)
  • No dose-response trends for duration and frequency of powder use were identified
  • In medically confirmed cases HR was attenuated for ever use vs never use
    • HR 1.05 (95% CI, 0.96 to 1.16)
  • When limited to women with a patent reproductive tract, an association was seen between powder ever use and ovarian cancer
    • Patent reproductive tract: HR 1.13 (95% CI, 1.01 to 1.26)
    • However, when comparing women with and without a patent reproductive tract, no differences were found between the group (P=0.15)

CONCLUSION:

  • The use of powder in the genital area was not significantly associated with incident ovarian cancer
  • However, the study may have been underpowered to detect a small increase in risk

Editorial (Gossett and Carmen; JAMA, 2020)

  • Talc structurally similar and can be found in same mines as asbestos | Powders no longer contain asbestos | If there is an association, underlying mechanism may be related to inflammation
  • Subgroup analysis of women with a patent reproductive tract did show a difference comparing ever to never users, but the effect size was below the threshold considered important by epidemiologists | The editorial authors caution that this result should not be selectively highlighted
  • The editorial authors also state that the absence of a significant difference when comparing women with and without patent reproductive tracts

…confirms the overall conclusion that there is no demonstrable statistically significant association between use of powder in the genital area and ovarian cancer risk

Learn More – Primary Sources:

Association of Powder Use in the Genital Area With Risk of Ovarian Cancer

Editorial: Use of Powder in the Genital Area and Ovarian Cancer Risk

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

Try it Free >>

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Does NSAID Use Impact Risk for Ovarian Cancer?
Do Contraceptives Decrease Risk for All Ovarian Cancers?
Antihistamine Use and Ovarian Cancer Risk

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Download Your ObG App
HERE!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site